PolymarketClosedCheck availabilityNo KYC2% feeVerified resolution dataFairly calibratedThis market resolved: No
Resolved: Jun 11, 2026, 9:52 AM
Provider-verified resolution
CoinRithm has provider-backed winner and settlement-time evidence for this market.
Winning Outcome
No
At 7 days out
—
At 24 hours out
8%
SurpriseCurrent implied probability
No 100%+0.9pt
Market quality
22 / 100
Low quality24h Volume
$933.9
Liquidity
—
Liquidity unknownBid / Ask
- / 0.4%
Market data
Updated 70 days ago
StaleJun 4, 26, 7:35 PMJun 10, 26, 12:00 AM
Probability Timeline
Yes0%
No100%
100%
0%
Rules
As of market creation, the FDA's expected decision date for the specified application is June 10, 2026.
- This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Camurus's Oclaiz as a treatment for patients with acromegaly by June 24, 2026, 11:59 PM ET.
- Otherwise, this market will resolve to "No."
- An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
